Therapeutic interventions for coronary microvascular obstruction after acute myocardial infarction: Developments and...

Area of Science:

• Cardiology
• Vascular Biology
• Translational Medicine

Background:

• ST-segment elevation myocardial infarction (STEMI) is a leading cause of death and heart failure globally.
• Primary percutaneous coronary intervention (PCI) improves epicardial reperfusion but microvascular obstruction (MVO) persists in many STEMI patients.
• MVO contributes to larger infarct size, adverse cardiac remodeling, and poorer long-term prognosis.

Purpose of the Study:

• To review the pathophysiological mechanisms underlying MVO in STEMI.
• To discuss current research methodologies and therapeutic strategies for MVO.
• To explore future directions for developing effective treatments to mitigate MVO and improve STEMI patient outcomes.

Main Methods:

• Literature review and synthesis of existing research on MVO in STEMI.
• Analysis of pathophysiological pathways including ischemia-reperfusion injury, endothelial dysfunction, and inflammation.
• Evaluation of preclinical and early-phase clinical trial data for novel MVO therapies.

Main Results:

• MVO is a complex process involving ischemia-reperfusion injury, endothelial dysfunction, distal embolization, inflammation, and pericyte-mediated constriction.
• Despite promising preclinical data, no definitive pharmacological or mechanical therapy has proven effective in large clinical trials.
• Current therapeutic approaches primarily focus on optimizing reperfusion and supportive care.

Conclusions:

• MVO remains a critical determinant of poor outcomes in STEMI patients despite advances in primary PCI.
• Further research into MVO mechanisms and rigorous clinical evaluation of novel therapies are essential.
• Developing targeted drugs or devices to limit MVO holds significant potential for improving STEMI prognosis.